MTOR and cancer: In favor of this, several studies suggested that even though often upregulated in cancers, targeting the mTOR pathway with its inhibitors brings only poor outcomes due to the promiscuity of signaling cascades and the plethora of possible targets that can be activated/deactivated depending on the microenvironment73.